Assessing the Frequency of Biologic DMARD Refractory Disease in Rheumatoid Arthritis

Psoriasis negatively affects patient sleep quality
September 25, 2018
Clinical trial proves to be ‘magic’ for Crohn’s treatment
September 25, 2018
Show all

Assessing the Frequency of Biologic DMARD Refractory Disease in Rheumatoid Arthritis

Biological medications are commonly used by those with rheumatoid arthritis.

At least 6% of patients with rheumatoid arthritis (RA) who have used biologic disease-modifying antirheumatic drugs (bDMARDs) in their lifetimes experience bDMARD refractory disease, according to a study recently published in the Annals of the Rheumatic Diseases.

This study included 13,502 individuals with RA who were initiating a first-line tumor necrosis factor inhibitor. Of these, 867 (6%) were bDMARD refractory, defined as having initiated a third class of bDMARD. It took a median time of 8 years to initiate the third class of bDMARD. Multivariable analysis showed correlations between bDMARD refractory disease and patients who were more recently registered, were younger, had a shorter duration of disease, were women, showed higher patient global assessment, had a higher score on the Health Assessment Questionnaire, were current smokers, had more social deprivation, and were obese.

Data in this study were part of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis, collected between 2001 and 2014. All follow-up was ceased no later than November 30, 2016. The study researchers examined reasons for stopping bDMARDs as well as switching patterns, and used Cox regression to gather baseline clinical characteristics that were related to refractory disease. Multiple imputation was used for missing baseline data.

Read on: Assessing the Frequency of Biologic DMARD Refractory Disease in Rheumatoid Arthritis

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.